DERM2025 News: J & J’s Icotrokinra Performs Well in High-impact PsO Sites
Johnson & Johnson’s icotrokinra showed significantly higher rates of overall skin, scalp, and genital psoriasis clearance and a favorable safety profile in adults and adolescents with psoriasis in these high-impact areas, according to a poster presented at DERM2025 in Las Vegas, NV. In ICONIC-TOTAL, the first Phase 3 study of the investigational oral interleukin (IL)-23 […]